proliferative diabetic retinopathy (PDR) with high risk characteristics
Conditions
Interventions
PRP group:panretinal photocoagulation
PRP combined with anti-VEGF therapy group:panretinal photocoagulation therapy combined with intravitreal injection of anti-neovascularization drugs
PPV group:pars plana vitrectomy
PPV combined with anti-VEGF therapy group:pars plana vitrectomy combined with intravitreal injection of anti-neovascularization drugs
Sponsors
Tianjin Medical University Eye Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. No gender limit, patients aged over 18 years. 2. Diagnosed with type 1 or type 2 diabetes. 3. According to the rating of China's Clinical Diagnosis and Treatment Guidelines for Diabetic Retinopathy (2014 Edition), the patient's DR Condition is high-risk PDR, and the criteria are as follows: Retinal neovascularization (NVE) or papillary neovascularization (NVD) occurs when NVD > 1/4-1/3 papillary diameter (DA) or NVE > 1/2DA, or is accompanied by preretinal or vitreous hemorrhage. 4. Best corrected vision > 0.05 (34 letters). 5. No previous RPR treatment history. 6. The dioptric medium is clear, and the pupil can be fully dilated to facilitate PRP treatment and obtain clearer OCT images and fundus color photography.
Exclusion criteria
Exclusion criteria: 1. Blood pressure >180/110 mmHg (1 kPa=7.5 mmHg) and other blood pressure control is not ideal. 2. Severe heart function, liver and kidney dysfunction. 3. Patients with severe cardiovascular and cerebrovascular diseases in the past 4 months. 4. Received anti-VEGF therapy in the past 2 months. 5. History of corticosteroid treatment within the past 4 months (intravitreous). 6. Patients with severe cataract, rheogenous retinal detachment, Eales disease and optic neuropathy were excluded. 7. Other patients with glaucoma, uveitis, retinal vascular obstruction, active periocular or intraocular inflammation. 8. The study eye had significant vitreoretinal fibroangiogenesis, vitreous hemorrhage, or traction retinal detachment. 9. Study eyes with iris or anterior chamber Angle neovascularization, or neovascular glaucoma.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Best corrected vision acuity; | — |
Secondary
| Measure | Time frame |
|---|---|
| CRT thickness;Macular volume; | — |
Countries
China
Contacts
Public ContactLiu Juping
Tianjin Medical University Eye Hospital
Outcome results
None listed